U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. FDA Bioresearch Monitoring Information
  5. Compliance Program Guidance Manual
  1. FDA Bioresearch Monitoring Information

Compliance Program Guidance Manual

Food and Drug Administration
Compliance Program Guidance Manual

PROGRAM
7348.808

 

Chapter 48
Bioresearch Monitoring
Date of Issuance: February 21, 2001
Guidance For FDA Staff

This document is intended to provide guidance. It represents the AgencyÂ’s current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind Food and Drug Administration (FDA) or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statute and regulations.

 

Subject
Good Laboratory Practice
(Nonclinical Laboratories)

Implementation Date
February 21, 2001

Completion Date
Continuing

Data Reporting
PRODUCT CODES PRODUCT/ASSIGNMENT CODES

51Z OR 52Z

 04808 Chemical Contaminants (EPA)

45Z, 46Z

 09808 Food Additives

57Z, 99Z

 41808 Biologics (Therapeutics)
42808 Biologics (Blood)
45808 Biologics (Vaccines)

60Z, 61Z

 48808 Human Drugs

68Z, 69Z

 68808 Animal Drugs

73Z, 74Z
94Z OR 95Z

 83808 Medical and Radiological Devices

Field Reporting Requirements

All establishment inspection reports (EIRs), complete with attachments, exhibits, and any post-inspectional correspondence are to be submitted promptly to the assigning Center. If an EIR contains serious findings raising the possibility of one or more violations of the Federal Food Drug & Cosmetic Act (FFDCA) or other Federal statutes, a copy of the EIR should be forwarded to the District Compliance Branch at the time it is sent to the Center. If an FDA-483 is issued, a copy will be faxed to the Center contact identified in the assignment.

If the district becomes aware of any significant adverse inspectional, analytical, or other information which may affect the agency's new product approval decisions with respect to a firm, the district should immediately notify the responsible Center program office via electronic mail, fax, or by phone.

If samples are collected for analysis, the analyzing laboratory will submit copies of the Collection Report and the Analytical Work sheets to the District Office and the assigning Center.

Hypertext updated April 3, 2001 tmc

Back to Top